Tin Men Capital

Tin Men Capital is a Singapore-based venture firm with a sharp B2B enterprise software thesis and a strong reputation among Southeast Asian founders building category-defining vertical SaaS. Within healthcare, Tin Men’s exposure is concentrated in Health IT and operational software for hospitals, clinics, and care providers rather than consumer health or pure AI plays. The firm writes $1M-$5M cheques at Seed and Series A and is comfortable leading rounds when the founder profile and market fit align. For founders, Tin Men is the right partner if you are building enterprise software for healthcare operators with multi-country ambitions across Singapore, Malaysia, Indonesia, Thailand, and the Philippines, and you can demonstrate paid pilots converting to multi-year contracts. Founders running consumer telehealth apps, pure AI research projects, or asset-heavy delivery models should not approach. The right introduction path is via a Tin Men portfolio CEO, the Singapore enterprise SaaS founder network, or regional accelerators like Antler and Iterative that frequently flow seed deals upward. Lead the pitch with annual contract value, gross retention, sales cycle length by buyer persona, and a clear ICP segmentation across SEA hospital tiers; abstract AI capability without enterprise-grade deployment evidence will not move them. Caveats: Tin Men runs a disciplined process with deep reference checks, and term sheets carry standard institutional terms. The firm is not an AI-first specialist, so AI-native founders should expect to defend model claims rigorously and may benefit from a technical co-investor. Founders should confirm reserves and follow-on policy explicitly, since concentrated positions in B2B SaaS often require meaningful Series A and B follow-on commitments to maintain ownership through dilution.